TSCAN THERAP.INC.DL-,0001 Aktie

The board approved a retention program for key employees: CEO Dr. Gavin MacBeath will receive a cash bonus of $822,000, Dr. Zoran Zdraveski $416,000. In addition, MacBeath is granted 2,400,000 and Zdraveski 1,050,000 Restricted Stock Units (RSUs); one‑third of the RSUs will vest upon reaching a financing milestone, with the remaining installments vesting over the following two years. The second half of the cash bonuses is tied to milestones of the in‑vivo program for solid tumors. The measures come against the backdrop of a strategic refocus on the in‑vivo TCR‑T program, the pause of the hematology program, analyst downgrades, and encouraging interim results from the phase‑1 ALLOHA‑1 study. » Więcej na de.investing.com

TScan Therapeutics has immediately suspended patient recruitment for the regulatory phase‑3 trial ALLOHA‑2™ for financial reasons and announced a reduction of about 75% of its workforce, the dissolution of its manufacturing department and a significant downsizing of research. The stock fell nearly 29% and hit a 52‑week low. Management expects cumulative cost savings of $55 million through the end of 2027; the updated cash runway now extends only to Q4 2027. Resources will be concentrated on two in vivo‑developed TCR‑T candidates for solid tumors (PRAME, MAGE‑A4) with a phase‑1 start targeted for Q4 2027, while the company seeks partners for the paused programs. » Więcej na de.investing.com

TScan treated the first patient in the phase‑3 ALLOHA‑2 trial with TSC‑101 after stem cell engraftment. The study is testing whether TSC‑101 prevents relapses after allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndromes compared with transplantation alone. Assignment is based on biological factors: A02:01‑positive patients with a suitable donor receive the treatment; the primary endpoint is relapse‑free survival, and key secondary endpoints are overall and event‑free survival. Topline data are expected in mid‑2028; the trial is actively ongoing in the US (NCT07702578). » Więcej na de.investing.com